2023/24赛季西班牙，为预防1例呼吸道合胞病毒（RSV）导致的住院病例，需要用尼塞韦单抗对婴儿进行免疫接种。
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season.
作者信息
Pastor-Barriuso Roberto, Núñez Olivier, Monge Susana
机构信息
National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
出版信息
Euro Surveill. 2025 Feb;30(6). doi: 10.2807/1560-7917.ES.2025.30.6.2500040.
Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77-108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35-50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.
利用西班牙2023年10月至2024年3月的实际生活数据，对于补种免疫，使用nirsevimab进行免疫接种所需人数（NNI）估计为90名婴儿（95%可信区间：77 - 108），预防1例呼吸道合胞病毒（RSV）住院的成本为19,700欧元；对于出生时免疫，所需人数为41名婴儿（95%可信区间：35 - 50），成本为9,000欧元。按出生月份来看，NNI和成本在RSV流行高峰前不久出生的婴儿中最低，对于更早或更晚出生的婴儿，影响逐渐降低。
Zotero 插件